Tyler Kashuv

Mr. Tyler Kashuv

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
HJHarrys Kishore Charles Jacob
Harrys Kishore Charles Jacob
John Lalith Charles RichardJohn Lalith Charles Richard
John Lalith Charles Richard
Rossana SignorelliRossana Signorelli
Rossana Signorelli
TKTyler Kashuv
Tyler Kashuv
SLshweta Lavania
shweta Lavania
ASAshok Saluja
Ashok Saluja
Tumor cells dissociate from the primary site and enter into systemic circulation (circulating tumor cells, CTCs) either alone or as tumor microemboli (clusters); the latter having an increased predisposition towards forming distal metastases than single CTCs. The formation of clusters is, in part, created by contacts between cell–cell junction proteins and/or cytokine receptor pairs with other cells such as neutrophils, platelets, fibroblasts, etc. In the present study, we provide evidence for an extravesicular (EV) mode of communication between pancreatic cancer CTCs and neutrophils. Our results suggest that the EV proteome of CTCs contain signaling proteins that can modulate degranulation and granule mobilization in neutrophils and, also, contain tissue plasminogen activator and other proteins that can regulate cluster formation. By exposing naïve neutrophils to EVs isolated from CTCs, we further show how these changes are modulated in a dynamic fashion indicating evidence for a deeper EV based remodulatory effect on companion cells in clusters.

9 September 2025 in World Journal for Pediatric and Congenital Heart Surgery
Verified
Journal Article
Closed access
ABAhmet Bilgili
Ahmet Bilgili
OSOmar M Sharaf
Omar M Sharaf
LKLiam Kugler
Liam Kugler
TKTyler Kashuv
Tyler Kashuv
ZBZachary Brennan
Zachary Brennan
JJJeffrey Phillip Jacobs
Jeffrey Phillip Jacobs
Background: This analysis evaluates the longitudinal impact of extracorporeal membrane oxygenation (ECMO) and ventricular assist device (VAD) on the progression of motor delay and cognitive delay in pediatric heart transplant recipients. Methods: The United Network for Organ Sharing Registry was queried for pediatric patients (<18 years) who received a heart transplant between 2008 and 2022 and were bridged-to-transplantation with either ECMO or VAD. Patients were further stratified based on the progression of delay status pretransplant to post-transplant. Results: A total of 827 patients were included in the final VAD cohort and 68 in the final ECMO cohort with 187/827 (22.6%) and 20/68 (29.4%) having progression of delay, respectively. Patients with progression of delay were more likely than those without progression of delay to have had a stroke prior to discharge (VAD: 14/187 (7.5%) vs. 16/640 (2.5%), P = .003; ECMO: 5/20 (25%) vs. 3/48 (6.25%), P = .043). VAD patients more often developed isolated delays (motor or cognitive only), whereas patients bridged-to-transplantation on ECMO more often had combined delays, with a cumulative incidence of combined delay at 3-years of 20.0% (95% CI = 8.94–34.20). Among VAD supported patients, those with progression of delay had worse 3-year survival compared with those without (91.20% [95% CI = 87.04–95.57%] vs. 94.97% [95% CI = 93.19–96.78], log-rank P = .04). Postoperative stroke was associated with an increased risk of progression of delay (OR = 2.39 [95% CI = 1.13–5.02] P = .021), and progression of delay was found to be an independent predictor of mortality (HR = 2.10 [95% CI = 1.35–3.25], P < .001). Conclusions: While overall rates of neurodevelopmental delay are similar between those bridged-to-transplantation with ECMO or VAD, the type of delay and associated survival varies.